Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05599659
Other study ID # REB22-0545
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 4, 2022
Est. completion date November 4, 2024

Study information

Verified date October 2022
Source University of Calgary
Contact Veronica Bruno, MD, MPH
Phone 4039194262
Email veronica.bruno@ucalgary.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to analyse the effect of palliative care interventions on quality of life, patient satisfaction, carepartner burden and health care utilization patterns in patients living with parkisonism and their carepartners. Participants will: - Receive multidisciplinary palliative care. - Answer questions related to the quality of life, patient satisfaction, carepartner burden and health care utilization patterns.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date November 4, 2024
Est. primary completion date November 4, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 100 Years
Eligibility Inclusion Criteria: - Participants who have a PD diagnosis or another PDRD diagnosis (multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, or Lewy body dementia) - Participants who have moderate to high PC needs based on the Palliative Care Needs Assessment Tool (PC-NAT) - Participants who are between 20 and 100 years old Exclusion Criteria: - Immediate and urgent palliative care needs. These patients will be offered appropriate services immediately - Participants who have other illnesses that could require PC e.g. metastatic cancer - Participants already receiving PC and/or hospice - Patients with a diagnosis of severe cognitive impairment (Montreal Cognitive Assessment <10). These patients will be offered appropriate services. Care partners can participate.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Palliative care
It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team. The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans. The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant.

Locations

Country Name City State
Canada Movement Disorder Program, Foothills Medical Center, Alberta Health Services Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Quality of Life Alzheimer's Disease (QOL-AD) The QOL-AD is a 13-item questionnaire designed to provide both a patient and a caregiver report of the quality of life (QOL), it uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the patient's physical health, mood, relationships, activities, and ability to complete tasks. Every 3 months for 2 years
Primary Changes in 12-Item Zarit Burden Interview (ZBI-12) ZBI-12 is validated as a screening tool for advanced illness. The ZBI-12 is rated on a 12 items scale, with the severity of burden using a range of responses from 0 to 4 points per item and a total score range of 0 to 48. Scoring 0-10 is considered as a no to mild burden; 10-20, a mild to moderate burden and >20, a high burden. It measures changes in physical, emotional, social, and financial problems that can be experienced by family caregivers. Every 3 months for 2 years
Primary Changes in Health Care Utilization survey We will perform a Health Service Utilization Survey to measure changes in the number of hospitalizations, emergency room visits, home health services, and nursing home placement. Every 3 months for 2 years
Secondary Changes in Edmonton Symptom Assessment Scale revised for Parkinson's Disease (ESAS-PD) The ESAS is a comprehensive, yet brief and practical self-reporting tool of symptom severity (intensity) for nine common symptoms of advanced cancer (pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, shortness of breath), with the option of adding a tenth patient-specific symptom. It rates the severity of each symptom on a 0 to 10 scale, where 0 represents the absence (or best possible intensity) of the symptom and 10 represents the worst possible severity. Every 3 months for 2 years
Secondary Changes in the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT- Sp-12) The 12-item Spiritual Well-Being Scale (FACIT-Sp-12) is the most widely used measure of spiritual well-being among those with long-term illness. The FACIT-Sp comprises 12 statements, or items, each of which is rated on a 5-point scale by the respondent based on how true the item was during the past week, 0 for not at all, 1 for a little bit, 2 for somewhat, 3 for quite a bit and 5 for very much. Every 3 months for 2 years
Secondary Semi-structured Qualitative Interview to receive Patient and Care Partner recommendations It will be performed on patients and care partners for optimizing the palliative care services provided and delivery methods. Every 3 months for 2 years
See also
  Status Clinical Trial Phase
Completed NCT06037590 - A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA® Phase 1
Enrolling by invitation NCT04799418 - STEM-PD Open Label Extension (OLE) N/A
Not yet recruiting NCT06074393 - Caregiving in Advanced PD: A Tailored Support Group N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT04140708 - Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease N/A
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Not yet recruiting NCT06400017 - Mechanism and Application of DBS in the Treatment of PD N/A
Recruiting NCT04797611 - STEM-Parkinson's Disease N/A
Not yet recruiting NCT06174948 - The Use of the CUE1 in People With Parkinson's Disease and Related Disorders N/A
Recruiting NCT05934747 - Aim 3 Particle Swarm Optimization PIGD N/A
Enrolling by invitation NCT04701177 - Digitally-enhanced, Decentralized, Multi-omics Observational Cohort
Recruiting NCT05962489 - Sleep-specific DBS Therapy in Parkinson's Disease N/A
Recruiting NCT05931692 - Virtual Reality and Fear of Falling in Parkinson's Disease
Recruiting NCT04468919 - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit N/A
Completed NCT04925622 - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Recruiting NCT04214509 - LIPAD - LRRK2 International Parkinson's Disease Study
Active, not recruiting NCT05677633 - Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease Phase 1
Recruiting NCT06350617 - Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients N/A
Recruiting NCT06247423 - High-frequency Alternating Current Stimulation for Tremor in Parkinson's Disease. N/A